# Step 244 — Independent mandatory-gap work closure

2026-10-29 (America/Toronto). **B. No further independent implementation justified. No code changes in this closure pass. All currently actionable internal mandatory-gap implementation work is exhausted within the documented seven-ID inventory and established contracts.** This is an engineering stop disposition, not certification closure. PC07.01 remains PARTIAL; all seven IDs remain open across three packages.

## 1. Scope, branch and preservation

The owner's latest Step 244 instruction controls: implement only demonstrated specification-backed omissions, defer external/unresolved contracts and stop rather than manufacture another development task.

Read AGENTS.md and inspected Git status once. Preserved **`feature/step-244-pc07-01-medication-retrieval`**, all six pre-existing tracked modifications, all untracked reports and manual work. The earlier Step 244 source/test correction is existing work at entry to this pass; it was neither undone nor presented as newly implemented here. Before/after hashes verified preservation of those source changes and reports 308–317.

Only this requested closure report was added. No branch change, commit, push, pull, fetch, merge, rebase, reset, clean, stash, database access, permission/configuration change or service operation occurred.

## 2. Exact requirements and alleged omissions examined

Reuse [Step 243](316-step243-mandatory-gap-dependency-reprioritization.md) and the bounded [Step 244 medication reconciliation](317-step244-pc07-01-medication-retrieval-reconciliation.md), including its complete field-to-owner/retrieval/audience matrix. No repository-wide scan, new supplier research or full certification reassessment was performed.

Source: [Primary Care Baseline Requirements 1.7 Final, March 20, 2026](</D:/MasterProgram_Ahmed/Ontario EMR Specification/Functional/Primary Care Baseline - 5.5 Final - 2026-05-04/Primary Care Baseline - 1.7 Requirements.pdf>), §2.7, printed pp.27–28, with the retained CDS-S medication ledger in [Step 115](150-step115-pc07-01-medication-de09-requirement-resolution.md).

> The EMR Offering MUST display Cumulative Patient Profile (CPP), identifying the summary of patient information.

PC07.01(f) requires Medication Summary. Related PC07.06 requires an ongoing medication treatment plan by default; current acute inclusion is permitted. The retained dictionary mapping identifies 36 mandatory medication elements, 23 S/D and 13 S. Neither that mapping nor PC07.01 requires every field on a compact card, printing every store-only field, a new audience, or an inferred plan/order association.

| Alleged omission / exact requirement reference | Existing implementation and evidence | Disposition |
| --- | --- | --- |
| Missing Medication Summary / PC07.01(f), PC07.06 | CPP medication section uses owned Active Ongoing plans by default; acute/unclassified and historical plans remain retrievable through the existing medication chart/detail paths | Covered under the existing native contract; no new CPP feature justified |
| Missing supported medication detail / PC07.01(f) and applicable DE09 S/D elements | Existing order API returns medication fields; preceding Step 244 added their omitted read-only rendering in the existing prescription detail destination | Correction already implemented and tested; preserve it, do not duplicate it |
| Missing field ownership / applicable DE09 elements and PC07.01(f) | Medication plan, prescription order, protected notes and frozen artifact remain independently owned; the preceding report maps all 36 elements to owner, retrieval and audience | Reconciliation recorded; no second source of truth or name-based join justified |
| Missing authorized audience / PC07.01(f) retrieval applicability | Existing authenticated tenant membership and Patients.View protect ordinary detail; protected notes have separate permission/service rules; no mandatory additional audience is established by the cited clause | Existing coverage retained. New external/provider/patient-portal audience would require a specified contract; do not invent one |
| Current versus historical treatment / PC07.06 | Ongoing treatment intent is separate from lifecycle; CPP plan default and finalized-order summary remain distinct, and order/plan history paths remain available | No new activity rule or history workflow justified. Finalized is not declared equivalent to active treatment |
| Wider authority / DE09.027 applicability | Existing native Yes/Not recorded paper-view contract is implemented; a broader No/electronic-authority declaration lacks the governing basis identified in retained evidence | Precise unresolved clinical/applicability contract; no speculative declaration or permission change |
| External/historical source and release applicability | Existing native mapping and source qualifications remain; no additional externally owned record/audience contract is established | Unresolved applicability/source evidence, not a demonstrated independently implementable field omission |

## 3. Implementation and focused evidence

**New implementation in this pass: NONE.** The preceding Step 244 correction changed `Views/PatientPrescriptions/Detail.cshtml` and `PrescriptionDetailDisplayTests.cs`. It exposed already stored/retrieved values without altering clinical data, permissions, CPP design or frozen artifacts. Its detailed implementation and field mapping remain in the preserved companion report.

Reused its existing TRX receipt at `.tmp/step244/medication-retrieval.trx`: **25 passed, 0 failed**. These are prior focused results, not a new test run: 24 production-view cases cover supported fields, nulls, partial dates, encoding and Draft/Finalized/Cancelled/Superseded states; one controller case covers ordinary-reader protected-note exclusion. Compilation used isolated artifacts. These results do not establish live middleware/database authorization or complete certification acceptance.

**Tests/builds executed in this closure pass: 0**, as no code changed. Checked the existing receipt, report links/whitespace and preservation hashes. No unrelated tests or regression suites were run.

## 4. Remaining mandatory inventory and dependencies

| Package | Requirement | Retained status / dependency |
| --- | --- | --- |
| Prescribing | PC04.01 | EXTERNAL, deferred; PARTIAL; COTS qualification unresolved |
| Prescribing | PC04.06 | EXTERNAL, deferred; interaction supplier/clinical contract unresolved |
| Prescribing | PC04.07 | EXTERNAL, deferred; licensed matching knowledge and clinical contract unresolved |
| Prescribing | PC04.09 | MIXED; actual alert/severity and effective threshold contract unresolved |
| Prescribing | PC04.14 | MIXED; authentic permitted licence metadata unavailable |
| CPP | PC07.01 | MIXED / PARTIAL; completed native retrieval correction retained; broader authority/source/audience applicability remains qualified |
| Scheduling | PC09.03 | BLOCKED; named billing receiver and transfer contract unresolved; no mandatory third-party vendor is inferred |

**Inventory unchanged: 7 mandatory IDs / 3 packages.** Deferral does not waive a requirement, remove it from inventory or mark it SATISFIED. No formal OntarioMD certification approval is claimed.

## 5. Stop disposition

No additional independently implementable, specification-backed mandatory omission is demonstrated under the current approved contracts. **Stop implementation work here.** Unresolved external inputs, clinical/applicability decisions and retained verification limitations remain visible; they are not automatically new product-development tasks.

The latest owner instruction supersedes any automatic continuation implied by the companion report's earlier “Recommended Step 245” section. That report and its historical evidence are preserved unchanged. This closure creates **no Step 245 implementation task**, proposes no substitute requirement and schedules no deployment, service restart or additional acceptance loop. Work can be reconsidered only if a concrete missing mandatory behavior or the specific unresolved inputs are established; no further implementation is recommended by this report.
